Moderna completes application to u.s. food and drug administration for emergency use authorization of omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222

Mrna-1273.222 targets ba.4/ba.5 strains of omicron variant pending authorization, moderna ready to ship bivalent booster mrna-1273.222 in september clinical data available for moderna's bivalent covid-19 booster vaccines have met all primary endpoints and support request for emergency use authorization cambridge, ma / accesswire / august 23, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it has completed its submission to the u.s. food and drug administration (fda) for emergency use authorization for its ba.4/ba.5 omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222. the application is for a 50 Μg booster dose for adults 18 years of age and older, and is based on preclinical data as well as clinical trial data available for the company's ba.1 omicron-targeting bivalent booster candidate, mrna-1273.214.
MRNA Ratings Summary
MRNA Quant Ranking